Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Larisa V. Gubareva"'
Autor:
Larisa V. Gubareva, Katrina Sleeman, Amanda Balish, Vasiliy P. Mishin, Rebecca Garten, Alicia M. Fry, Julie Villanueva, Zhu Guo, James Stevens
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:2045-2051
Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not
Autor:
Michael W. Shaw, Rebecca Garten, Larisa V. Gubareva, Alexander Klimov, Margaret Okomo-Adhiambo, Vasiliy P. Mishin, Tiffany G. Sheu, Varough M. Deyde, Ha T. Nguyen, A. Angelica Trujillo, Alicia M. Fry, Katrina Sleeman
Publikováno v:
Antiviral Therapy. 15:1151-1159
Background Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010. Me
Publikováno v:
Antiviral Research. 53:47-61
We previously characterized influenza viruses whose selection in the presence of neuraminidase (NA) inhibitors resulted in a substituted residue (position 119, 152, 274, or 292) in the NA active center. To identify the most favorable conditions for d
Autor:
Margaret Okomo-Adhiambo, Larisa V. Gubareva, Katrina Sleeman, Zhu Guo, Ha T. Nguyen, Xiyan Xu, James Stevens, Hua Yang, Vasiliy P. Mishin, Marnie Levine, Daisuke Tamura
Publikováno v:
Antimicrobial agents and chemotherapy. 57(12)
Assessment of drug susceptibility has become an integral part of influenza virus surveillance. In this study, we describe the drug resistance profile of influenza A(H3N2) virus, A/Mississippi/05/2011, collected from a patient treated with oseltamivir
Autor:
Mikhail Matrosovich, Robert G. Webster, Richard C. Bethell, Malcolm K. Brenner, Larisa V. Gubareva
Publikováno v:
The Journal of Infectious Diseases. 178:1257-1262
Zanamivir, a neuraminidase inhibitor, has shown promise as a drug to control influenza. During prolonged treatment with zanamivir, a mutant virus was isolated from an immunocompromised child infected with influenza B virus. A hemagglutinin mutation (